Research Funded by Next Generation Labs Shows Huge Promise

Research Funded by Next Generation Labs Shows Huge Promise

Specific Nicotine Isomers Ratios Could Potentially Offer Nicotine use at Satisfying but Non-Addictive Levels as Revealed in Next Generation Labs Research

Research funded by Next Generation Labs shows huge promise in novelty ‘R’ and ‘S’ enantiomer isomers as new intellectual property filings are underway

Next Generation Labs, the maker of the world’s only patented synthetic nicotine is pleased to report some novel findings related to its research on the isomeric character of the company’s patented synthetic nicotine products.

Vincent Schuman, CEO of Next Generation Labs, stated that “our work with a highly respected USA-based research lab has revealed a novel relationship between the active ‘S’ isomer in synthetic nicotine and the assumed less-active ‘R’ nicotine isomer.”

Although preliminary and confidential, the findings gave some “surprising and unexpected” results according to a well-recognized FDA approved research laboratory. The studies revealed that specific ratios of the ‘R’ to the ‘S’ isomers could potentially offer nicotine use at satisfying but non-addictive or less addictive levels.

Although the research findings are in their early stages, Next Generation Labs, which has applied for a number of novel use patents for synthetic ‘R’ and ‘S’ nicotine isomers in vaping, tobacco and in pharmaceutical drug development related to R and S isomer concentration, believes this early stage research will help strengthen its Intellectual Property portfolio going forward.

Additionally, Schuman added that this initial study could help redefine novel nicotine research and current thinking about nicotine, as Next Generation Labs is the only Company that has been able to successfully commercially scale production levels of pure all ‘S’ nicotine and pure all ‘R’ nicotine, and make the pure isomeric forms available in large volumes to industry and academia. Consequently, this is the first time that vape, tobacco and pharmaceutical industries can all start to think about new product development in the context of proportional combinations of ‘R’ to ‘S‘ isomer as a form of possible dosage control, rather than the current simplistic measure of total nicotine concentration by volume.

“We are aware of a number of products on the market that claim to be synthetic nicotine, that are starting to make similar claims for the use and application of this product. Next Generation Labs intends to monitor the market, and competitor claims, and intends to vigorously enforce its current and pending patents in this unique research space.”
-Vincent Schuman, CEO of Next Generation Labs

For further information about Next Generation Labs and TFN Nicotine please contact Vincent Schuman here.

 

 

Comments are closed.